| Literature DB >> 28970536 |
Andreas Neueder1, Theresa A Gipson2, Sophie Batterton3, Hayley J Lazell3, Pamela P Farshim3, Paolo Paganetti4,5, David E Housman2, Gillian P Bates6.
Abstract
The heat shock response (HSR) is a mechanism to cope with proteotoxic stress by inducing the expression of molecular chaperones and other heat shock response genes. The HSR is evolutionarily well conserved and has been widely studied in bacteria, cell lines and lower eukaryotic model organisms. However, mechanistic insights into the HSR in higher eukaryotes, in particular in mammals, are limited. We have developed an in vivo heat shock protocol to analyze the HSR in mice and dissected heat shock factor 1 (HSF1)-dependent and -independent pathways. Whilst the induction of proteostasis-related genes was dependent on HSF1, the regulation of circadian function related genes, indicating that the circadian clock oscillators have been reset, was independent of its presence. Furthermore, we demonstrate that the in vivo HSR is impaired in mouse models of Huntington's disease but we were unable to corroborate the general repression of transcription that follows a heat shock in lower eukaryotes.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28970536 PMCID: PMC5624871 DOI: 10.1038/s41598-017-12897-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Development of an in vivo heat shock protocol. (A) Schematic depicting the treatment and processing pipeline used in this publication. WT = wild type; Hsf1 −/− = Hsf1 homozygous knockout mice; R6/2 = mouse model for Huntington’s disease. (B) Thermal camera images of exemplary mice before or after heat shock from the dorsal and ventral side. Control mice (control) were kept at 36.9 °C; heat shocked mice (HS) were subjected to a 15 minute heat shock at 41.5 °C. Quantification of the data is shown (right panel). Data are mean ± SEM; n ≥ 4; two-way ANOVA with Tukey post hoc test. (C) Time course of tail temperature (mins) from start of the procedure (T-4), beginning of the 15 minutes (T0) until the end of the heat shock (T+15). (D) Temperature differences as measured by thermal camera imaging between control and heat shocked animals. Quantification (lower right panel) was done by calculating the average temperature for each mouse across the treatment. Data are mean ± SEM; n ≥ 4 for forehead and neck, n ≥ 3 for tail; two-tailed homoscedastic Student’s t-test. (E) Kinetics of transcript induction of 3 HSP genes (Hspa1a/b, Dnajb1, Hspb1) and Hsf1 from 0 to 8 hours after heat shock in quadriceps femoris muscle of 12 week old wild type mice. Data are mean ± SEM relative to the expression levels of each gene in the respective untreated group at 0 hours; n = 4; two-tailed homoscedastic Student’s t-test. (F) HSF1 protein analysis of the same samples as in (E). Both panel shows exemplary results for each time point. ATP5B was used as a loading control. Treatment: *p < 0.05, **p < 0.01, ***p < 0.001 and pre- / post-HS ### p < 0.001.
Figure 2The heat shock response is impaired in the R6/2 mouse model of Huntington’s disease. (A) Heat map showing the basal transcript levels of several heat shock response genes and regulators in cortex, liver, quadriceps femoris (quad. fem.) and tibialis anterior (tib. ant.) muscles at different stages (E14.5 = embryonic day 14.5; p7 = postnatal day 7; wk = weeks). Data are the log2 fold changes of R6/2 vs. wild type mice. Data are mean ± SEM; n = 4; two-tailed homoscedastic Student’s t-test. Genotype: *p < 0.05, **p < 0.01, ***p < 0.001. (B) Transcript induction at 4 hours after heat shock or HSP90 inhibition (HSP990) in quadriceps femoris muscle of R6/2 and wild type mice at 12 week of age. Data are mean ± SEM relative to the levels of control or vehicle treated wild type animals; n ≥ 6; two-way ANOVA with Tukey post hoc test. (C and D) Heat shock protein induction at 24 hours after heat shock (HS) (C) or HSP90 inhibition (HSP990) (D) in quadriceps femoris muscle of R6/2 and wild type mice at 12 week of age. Data are mean ± SEM relative to the levels of control or vehicle treated wild type animals; n ≥ 6; two-way ANOVA with Tukey post hoc test. TUBA1a/b was used as a loading control. (B,C and D) Treatment: *p < 0.05, **p < 0.01, ***p < 0.001 and treatment/genotype # p < 0.05, ## p < 0.01, ### p < 0.001.
Figure 3The heat shock response is impaired in the HdhQ150 mouse model of Huntington’s disease. (A) Transcript induction at 4 hours after heat shock in quadriceps femoris muscle of homozygous HdhQ150 and wild type mice at 21-22 months of age. Data are mean ± SEM relative to the levels of control wild type animals; n ≥ 5; two-way ANOVA with Tukey post hoc test. (B) Heat shock protein induction at 24 hours after heat shock in quadriceps femoris muscle of homozygous HdhQ150 (Q150/Q150) and wild type (+/+) mice at 21–22 months of age. Data are mean ± SEM relative to the levels of control wild type animals; n ≥ 4; two-way ANOVA with Tukey post hoc test. TUBA1a/b was used as a loading control. Treatment: *p < 0.05, **p < 0.01, ***p < 0.001 and treatment/genotype # p < 0.05, ## p < 0.01, ### p < 0.001.
Gene ontology enrichment analysis for heat shock treated mice.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| WT control vs. HS | up | 570 | 1: CLOCK 315.2, HSF1 302.42, ESR1 210.21, TCFAP2C 149.06, PPARG 143.32: MYOD1 55.7, MYOG 42.06, HSF1 41.33, EP300 34.79, ZMIZ1 34.45 | 1: Adipogenesis 23.72, Diurnally Regulated Genes with Circadian Orthologs 9.86, MAPK Signaling Pathway 8.47, Aryl Hydrocarbon Receptor 6.672: Attenuation phase (of HSF1) 26.5, HSF1-dependent transactivation 23.52, Cellular response to heat stress 16.7 | response to topologically incorrect protein 39.17, protein refolding 28.18, regulation of p38MAPK cascade 21.76, cellular response to lipid 16.21, regulation of vasculature development 14.86 | IRAK4 122.8ILK 83.21IGF1R 56.46ITK 42.54EGFR 41.07 | H3K4me1 36.38H3K27me3 27.61H3K27ac 19.79 |
| down | 264 | 1: WT1 86.33, NANOG 81.37, POU5F1 80.23, EP300 66.67, ZFP281 63.942: MAZ 14.9, EP300 12.0, GATA2 10.61, MYOD1 10.53, TCF3 9.86 | 1: not significant2: Signaling by BMP 13.73, Defective SLC26A2 causes chondrodysplasias 7.29, Extracellular matrix organization 7.19, Defective EXT1 causes exostoses 1, TRPS2 and CHDS 7.18, Oncogene Induced Senescence 7.11 | cellular response to lipid 21.06, receptor protein serine/threonine kinase signaling pathway 18.85, BMP signaling pathway 18.08, positive regulation of endothelial cell migration 17.62, regulation of smooth muscle cell migration 15.15 | IRAK4 41.39FGFR1 31.01CDK8 19.9BMPR2 10.99KSR2 8.7 | H3K27me3 31.73H3K4me3 23.62H3K4me1 17.47 | |
| R6/2 control vs. HS | up | 89 | 1: CLOCK 69.16, STAT3 45.91, ESR1 40.48, SUZ12 34.81, EGR1 33.552: not significant | 1: Corticotropin-releasing hormone 7.05, AGE/RAGE pathway 6.15, Diurnally Regulated Genes with Circadian Orthologs 5.052: HSF1 activation 11.17, Attenuation phase (of HSF1) 11.09, HSF1-dependent transactivation 10.9, Cellular response to heat stress 8.24 | cellular response to lipid 15.92, cellular response to hormone stimulus 13.81, negative regulation of calcium ion transport 11.38, response to temperature stimulus 11.12, nitric oxide mediated signal transduction 10.37 | IRAK4 20.98AKT1 20.3RAF1 16.98CDK8 9.51ROCK1 8.63 | H3K9me3 13.86H3K27me3 10.28H3K4me1 10.24 |
| down | 20 | 1: EP300 19.44, KLF4 7.98, VDR 7.96, GATA2 7.00, DNAJC2 7.002: not significant | 1: Striated Muscle Contraction 13.98, Retinol metabolism 8.342: Striated Muscle Contraction 8.19, Signaling by Retinoic Acid 7.79 | actin-myosin filament sliding 17.2, negative regulation of cartilage development 13.33, response to leptin 5.41 | FGFR1 6.61AKT1 5.56 | not significant | |
|
| up | 239 | 1: ESR1 134.55, CLOCK 108.64, STAT3 91.19, MTF2 80.56, ZNF217 76.022: MYOD1 29.47, ESR1 21.0, STAT3 18.65, TCF12 18.6, RAD21 18.36 | 1: Adipogenesis 14.47, Oncostatin M Signaling Pathway 9.54, Spinal Cord Injury 9.08, Diurnally Regulated Genes with Circadian Orthologs 8.872: not significant | response to oxygen levels 13.14, regulation of heart contraction 12.63, negative regulation of phosphorylation 11.29, negative regulation of cell migration 10.48, Rho protein signal transduction 10.29 | IRAK4 70.63KSR1 35.67CDK8 27.78HUNK 23.99IGF1R 19.05 | H3K4me1 28.94H3K27me3 24.01H3K9me3 22.37 |
| down | 103 | 1: TCF3 41.25, PPARG 37.09, CLOCK 32.42, POU5F1 28.47, POU3F2 28.472: GATA2 5.63 | 1: Striated Muscle Contraction 17.28, PPAR signaling pathway 12.95, Adipogenesis genes 7.35, SIDS Susceptibility Pathways 5.782: Striated Muscle Contraction 14.29 | muscle filament sliding 24.95, circulatory system process 11.09, positive regulation of osteoclast differentiation 9.22, fat cell differentiation 8.75, lipid storage 8.65 | CDK8 24.31ILK 21.09FGFR1 20.89AKT2 12.6IRAK4 8.16 | H3K27me3 19.97H3K9me3 13.08H3K9ac 7.42 |
Upstream regulators were predicted using the ChIP-x Enrichment Analysis (1: ChEA) and ENCODE transcription factor ChIP-seq database 2015 (2: ENCODE).v Chromatin marks were predicted using the ENCODE histone modifications database 2015. Only the top non-redundant significantly enriched terms followed by their combined score are shown. See also Tables S1, S2, S5, S6 and S8.
Gene ontology enrichment analysis for HSP990 treated mice.
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| WTvehicle vs. HSP990 | up | 479 | 1: HSF1 382.44, ESR1 177.22, CLOCK 143.11, EP300 131.96, TCF21 130.52: HSF1 67.04, TCF12 56.90, MYOD1 53.53, GATA3 38.37, TCF3 36.89 | 1: Focal Adhesion 26.64, Inflammatory Response Pathway 16.87, IL-2 Signaling Pathway 9.78, Apoptosis-related network due to altered Notch3 in ovarian cancer 9.42, Type II interferon signaling 8.592: Extracellular matrix organization 61.98, Collagen biosynthesis and modifying enzymes 32.3, Attenuation phase (of HSF1) 25.24, HSF1 activation 24.29, Scavenging by Class A Receptors 12.71 | extracellular matrix organization 96.51, collagen fibril organization 43.4, protein folding 43.24, response to wounding 23.12, response to acid chemical 19.93 | IRAK4 158.7KSR1 83.98CDK8 72.45BMPR2 62.38FGFR1 42.72 | H3K27me3 37.46H3K27ac 28.67H3K4me1 26.28 |
| down | 195 | 1: CLOCK 95.44, TAF7L 90.88, SOX2 60.96, FOXP2 57.93, TCFAP2C 51.392: RFX5 18.54, POLR2A 13.64, E2F1 13.31, EP300 10.71, MAZ 10.24 | 1: not significant2: not significant | response to peptide 7.13, organic acid transport 6.77, cellular response to oxidative stress 6.68, positive regulation of p38MAPK cascade 6.62, negative regulation of lipid storage 5.48 | ILK 24.46IRAK4 24.10IGF1R 16.38HUNK 14.21KSR2 13.27 | H3K4me1 13.05H3K27me3 10.84H3K4me3 9.79 | |
| R6/2vehicle vs. HSP990 | up | 149 | 1: HSF1 232.59, CLOCK 51.98, TRIM28 36.67, SUZ12 35.25, E2F1 32.962: HSF1 53.66, STAT2 10.42, STAT1 10.03, EP300 9.31, FOSL1 9.24 | 1: IL-4 Signaling Pathway 6.42, Apoptosis Modulation and Signaling 6.14Adipogenesis 6.06, MAPK Signaling Pathway 5.35, SIDS Susceptibility Pathways 5.122: HSF1 activation 39.15, Attenuation phase (of HSF1) 39.11 | protein folding 32.7, regulation of apoptotic signaling pathway 13.91, negative regulation of phosphorylation 12.27, regulation of cytokine production 11.32, response to interferon-alpha 8.11 | CDK8 34.46ILK 20.06ROCK2 18.68IRAK4 13.52ROCK1 13.48 | H3K4me3 13.07H3K4me1 8.03H4K20me1 6.73 |
| down | 249 | 1: CLOCK 101.11, NANOG 80.97, ESR1 78.05, MTF2 70.52, PPARG 66.172: TCF12 15.54, CTCF 15.46, NFIC 14.83, ZC3H11A 14.13, UBTF 13.55 | 1: Adipogenesis 11.53, Signaling Pathways in Glioblastoma 7.63, EGF/EGFR Signaling Pathway 5.48, MAPK Signaling Pathway 5.472: Signaling by EGFR 6.47, Signalling by NGF 6.4, Downstream signaling of activated FGFR 6.18, Signaling by ERBB2 6.04, Signaling by FGFR 6.03 | cellular response to nitrogen compound 15.21, regulation of vasculature development 13.83, positive regulation of lipase activity 13.57, Ras protein signal transduction 12.82, positive regulation of reactive oxygen species metabolic process 12.41 | IGF1R 37.05KSR2 33.07IRAK4 31.62HUNK 24.12ROCK2 10.21 | H3K27me3 38.44H3K4me1 33.46H3K9me3 12.79 | |
|
| up | 72 | 1: TAF7L 47.7, ATF3 43.03, STAT3 42.39, SOX2 36.48, E2F1 35.422: CEBPB 47.9, CHD1 28.94, JUN 26.57, MAX 22.46, FOSL2 21.12 | 1: Hypertrophy Model 14.84, MAPK signaling pathway 6.282: PERK regulates gene expression 13.76, ATF4 activates genes 13.62, Amino acid transport across the plasma membrane 13.13, Amino acid synthesis and interconversion (transamination) 9.97, Unfolded Protein Response (UPR) 6.99 | response to endoplasmic reticulum stress 17.21, response to unfolded protein 17.1, amino acid transmembrane transport 16.99, anion transmembrane transport 16.72, apoptotic signaling pathway 16.07 | KSR1 38.98EGFR 30.53ALK 24.9IRAK4 21.98SNRK 16.38 | H3K36me3 10.33H3K4me1 8.64H3K27me3 7.21 |
| down | 40 | 1: KLF4/5/2 22.37, SMAD4 18.72, SMARCA4 18.57, SMAD3 16.92, ZFP281 15.52: not significant | 1: Striated Muscle Contraction 8.062: Muscle contraction 10.87, Signaling by NOTCH4 5.39, | negative regulation of ERK1 and ERK2 cascade 9.92, actin-myosin filament sliding 9.45, negative regulation of intracellular signal transduction 9.41, cellular response to fluid shear stress 9.0, regulation of endothelial cell differentiation 8.77 | KSR2 7.91 | H3K27me3 6.32 |
Upstream regulators were predicted using the ChIP-x Enrichment Analysis (1: ChEA) and ENCODE transcription factor ChIP-seq database 2015 (2: ENCODE). Chromatin marks were predicted using the ENCODE histone modifications database 2015. Only the top non-redundant significantly enriched terms followed by their combined score are shown. See also Tables S3, S4, S5, S7 and S9.
Figure 4Differential systemic response to HSP90 inhibition in R6/2 compared to wild type mice. (A) Scatter plot showing the significant log2 fold changes at 4 hours after HSP90 inhibition (HSP990) in quadriceps femoris muscle of R6/2 and wild type mice at 12 week of age. Each dot represents a gene. Lanes 1 and 2 represent the significantly regulated genes through HSP90 inhibition in R6/2 or wild type mice. Lanes 3 to 5 show the common (lane 3) and distinct (lanes 4 and 5) responses to treatment. Lane 6 compares HSP990 treated R6/2 with HSP990 treated wild type mice. Here, we corrected for differences due to the genotype by subtracting the log2 fold changes of significantly different genes (genotype) from their log2 induction value (HSP990). Only genes with a resulting fold change of ≥1.25 were considered for further analysis. (B) Chromatin mark predictions for genes shown in (A). Only significantly enriched chromatin marks (p < 0.001) were considered. We used the combined score, which is the product of the p-value with the z-score of the deviation from the expected rank, as a measure for prediction quality. Together, the average (y-axis) and the sum (circle diameter) of the combined scores are a good indicator of the confidence of the chromatin mark predictions. (C) Venn diagram and transcription factor network of common and distinct responses to HSP90 inhibition in R6/2 and wild type mice. Data correspond to lanes 3, 4 and 5 in (A) and (B). Numbers indicate the number of significantly regulated genes. To predict upstream regulators, we created gene lists for significantly regulated (up and down combined) genes for each condition and used the ENCODE transcription factor ChIP-seq database (2015) to identify the significantly enriched transcription factors (n ≤ 10 with a combined score of ≥ 5). Circle diameter is an indicator of the confidence of the predictions. See also Figures S2, S5 and S6.
Figure 5Differential systemic response to heat shock in Hsf1 knockout compared to wild type mice. (A) Scatter plot as described in Fig. 4A showing the log2 fold transcriptome wide changes at 4 hours after heat shock (HS) in quadriceps femoris muscle of Hsf1 knockout (Hsf1 −/−) and wild type mice at 10–12 week of age. (B) Chromatin mark predictions for genes shown in (A). Chromatin Marks prediction was as described in Fig. 4B. (C) Venn diagram and transcription factor network of common and distinct responses to heat shock in Hsf1 knockout and wild type mice. Data correspond to lanes 3, 4 and 5 in (A) and (B). Upstream regulator prediction was as described in Fig. 4B.